The "Global Anaplastic Lymphoma Kinase (ALK) Inhibitors Market 2020-2024" report has been added to ResearchAndMarkets.com's offering.
The anaplastic lymphoma kinase (ALK) inhibitors market is poised to grow by $2.96 bn during 2020-2024 progressing at a CAGR of 20% during the forecast period.
The reports on anaplastic lymphoma kinase (ALK) inhibitors market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the high target affinity and specificity of ALK inhibitors and high prevalence of lung cancer. In addition, high target affinity and specificity of ALK inhibitors is anticipated to boost the growth of the market as well.
This study identifies by the presence of patient assistance programs as one of the prime reasons driving the anaplastic lymphoma kinase (ALK) inhibitors market growth during the next few years. The author presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters.
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading anaplastic lymphoma kinase (ALK) inhibitors market vendors that include AstraZeneca Plc, Betta Pharmaceuticals Co. Ltd., Bio-Techne Corp., F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Merck KGaA, Novartis AG, Pfizer Inc., Takeda Pharmaceutical Co. Ltd., and Turning Point Therapeutics Inc..
Also, the anaplastic lymphoma kinase (ALK) inhibitors market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
Key Topics Covered:
Value chain analysis
Market segment analysis
Market size 2019
Market outlook: Forecast for 2019 - 2024
Five Forces Analysis
Five forces summary
Bargaining power of buyers
Bargaining power of suppliers
Threat of new entrants
Threat of substitutes
Threat of rivalry
Market Segmentation by Type
Comparison by Type
Second-generation ALK inhibitors - Market size and forecast 2019-2024
First-generation ALK inhibitors - Market size and forecast 2019-2024
Third-generation ALK inhibitors - Market size and forecast 2019-2024
Market opportunity by Type
North America - Market size and forecast 2019-2024
Europe - Market size and forecast 2019-2024
Asia - Market size and forecast 2019-2024
ROW - Market size and forecast 2019-2024
Key leading countries
Market opportunity by geography
Volume drivers - Demand led growth
Volume drivers - External factors
Market positioning of vendors
Betta Pharmaceuticals Co. Ltd.
F. Hoffmann-La Roche Ltd.
Takeda Pharmaceutical Co. Ltd.
Turning Point Therapeutics Inc.
For more information about this report visit https://www.researchandmarkets.com/r/9rtdm4
View source version on businesswire.com: https://www.businesswire.com/news/home/20201030005484/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900